Repligen Corporation $RGEN Stock Position Raised by Northern Trust Corp

Key Points

• Northern Trust Corp has increased its stake in Repligen Corporation by 1.0%, now holding 498,447 shares valued at approximately $63.4 million.
• Other institutional investors have also boosted their positions in Repligen, with Point72 Asset Management increasing its stake by 183.1% in the fourth quarter, owning over 918,000 shares.
• Repligen reported $182.37 million in revenue for the most recent quarter, a 14.8% increase year-over-year, although it missed earnings expectations with $0.37 per share.

Northern Trust Corp increased its stake in Repligen Corporation (NASDAQ:RGEN - Free Report) by 1.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 498,447 shares of the biotechnology company's stock after purchasing an additional 4,734 shares during the quarter. Northern Trust Corp owned about 0.89% of Repligen worth $63,422,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Raiffeisen Bank International AG acquired a new position in Repligen during the fourth quarter worth about $29,000. Itau Unibanco Holding S.A. acquired a new position in Repligen during the fourth quarter worth about $40,000. Signaturefd LLC grew its holdings in Repligen by 65.3% during the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock worth $41,000 after acquiring an additional 128 shares during the period. Center for Financial Planning Inc. grew its holdings in Repligen by 110.3% during the first quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock worth $47,000 after acquiring an additional 193 shares during the period. Finally, UMB Bank n.a. grew its holdings in Repligen by 99.4% during the first quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company's stock worth $85,000 after acquiring an additional 332 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Repligen Stock Up 0.1%

Repligen stock traded up $0.15 during mid-day trading on Friday, hitting $122.32. The company's stock had a trading volume of 651,937 shares, compared to its average volume of 722,374. Repligen Corporation has a 52-week low of $102.96 and a 52-week high of $182.52. The company has a market cap of $6.88 billion, a PE ratio of -489.26, a price-to-earnings-growth ratio of 2.25 and a beta of 1.07. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The firm's 50 day moving average is $121.74 and its 200 day moving average is $130.10.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The business had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. During the same quarter in the previous year, the business posted $0.40 earnings per share. The company's revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current year.

Insider Buying and Selling

In other Repligen news, Director Martin D. Madaus acquired 1,800 shares of the firm's stock in a transaction on Friday, August 8th. The stock was purchased at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the transaction, the director owned 1,800 shares of the company's stock, valued at $201,834. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.20% of the company's stock.

Wall Street Analysts Forecast Growth

RGEN has been the topic of a number of research analyst reports. Royal Bank Of Canada lifted their target price on Repligen from $193.00 to $204.00 and gave the stock an "outperform" rating in a report on Wednesday, July 30th. Barclays initiated coverage on Repligen in a report on Tuesday, June 24th. They set an "overweight" rating and a $150.00 target price on the stock. Evercore ISI lowered their target price on Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a report on Tuesday, July 8th. HC Wainwright reaffirmed a "buy" rating and set a $180.00 target price on shares of Repligen in a report on Monday, May 5th. Finally, Wells Fargo & Company decreased their price target on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research report on Wednesday, July 30th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $169.45.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.